Leslie M. Williams

Leslie M. Williams

Family Medicine

201 S. Sara Road
Suite 200
Mustang, OK 73064

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial).

Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial).

Journal: Pain

Published: July 27, 2017

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Journal: Nature

Published: June 23, 2017

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: June 20, 2016

Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

Journal: British journal of clinical pharmacology

Published: October 30, 2015

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Journal: Nature

Published: July 20, 2015

Showing 1-5 of 5

Last Updated: 09/26/2026